MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,EGFRX	SA00054272	57	M	SA00054272
Ordering Phys CLIENT,CLIENT				**DOB** 06/15/1955
Client Order # SA00054272	**Account Information**			**Report Notes**
Collected 02/27/2013	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 03/12/2013 14:00				

Test	Flag	Results	Unit	Reference Value	Perform Site*
Lung Cancer, EGFR with ALK Reflex		REPORTED 02/27/2013 15:58			
Specimen		Tissue-Tumor			MCR
Specimen ID		1039517			MCR
Order Date		27 Feb 2013 08:06			MCR
Reason for Referral					MCR
Evaluate tumor DNA for presence of a mutation in exons 18-21 of the EGFR gene.					
Method					MCR
Microscopic examination was performed by a pathologist to identify areas of tumor for enrichment by macrodissection. A PCR based assay employing allele specific amplification was used to test for the presence of 29 mutations within exons 18-21 of the EGFR gene (G719A, G719S, G719C in exon 18; small deletions in exon 19; T790M, S768I, and small insertions in exon 20; and L858R and L861Q in exon 21). Mutation nomenclature is based on GenBank accession number; NM005228.3.					
Result					MCR
Tumor type: Non-small cell lung cancer					
EGFR status: Mutant: A mutation was detected at codon Gly719					
Interpretation					MCR

Current data suggests that patients with non small cell lung cancer with mutations in the tyrosine kinase domain (exons 18-21) of EGFR may respond to EGFR tyrosine kinase inhibitor therapies. Therefore, the detection of an EGFR mutation within this tumor specimen suggests that this patient may respond to such therapies.

The predictive value of EGFR testing applies to EGFR tyrosine kinase inhibitor therapies, not to other therapeutic agents. Additionally, please note that not all patients that have mutant EGFR tumors respond to EGFR tyrosine kinase inhibitor therapies.

It is estimated that this panel detects greater than 95% of pathogenic mutations (exons 18-21) associated with response/resistance to EGFR targeted therapies.

Consideration of these results, in light of other clinical information, may aid in clinical management decisions for this patient.

CAUTIONS:

Performing Site Legend on Last Page of Report

* Report times for Mayo performed tests are CST/CDT

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,EGFRX	SA00054272	57	M	SA00054272
Ordering Phys CLIENT,CLIENT				**DOB** 06/15/1955
Client Order # SA00054272	**Account Information**			**Report Notes**
Collected 02/27/2013	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 03/12/2013 14:00				

Test	Flag	Results	Unit	Reference Value	Perform Site*
Rare polymorphisms exist that could lead to false negative or false positive results. Test results should be interpreted in context of clinical findings, tumor sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.					
For research use only.					
Reviewed By: Kandelaria Margarita Rumilla MD					MCR
Release Date		27 Feb 2013 15:55			MCR

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: